BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 26052067)

  • 1. Serum N-glycan profiles in patients with intraductal papillary mucinous neoplasms of the pancreas.
    Akimoto Y; Nouso K; Kato H; Miyahara K; Dohi C; Morimoto Y; Kinugasa H; Tomoda T; Yamamoto N; Tsutsumi K; Kuwaki K; Onishi H; Ikeda F; Nakamura S; Shiraha H; Takaki A; Okada H; Amano M; Nishimura S; Yamamoto K
    Pancreatology; 2015; 15(4):432-8. PubMed ID: 26052067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison between intraductal papillary neoplasms of the biliary tract (BT-IPMNs) and intraductal papillary mucinous neoplasms of the pancreas (P-IPMNs) reveals distinct clinical manifestations and outcomes.
    Minagawa N; Sato N; Mori Y; Tamura T; Higure A; Yamaguchi K
    Eur J Surg Oncol; 2013 Jun; 39(6):554-8. PubMed ID: 23506840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of malignancy in pure branch duct type intraductal papillary mucinous neoplasm of the pancreas: A nationwide multicenter study.
    Kim TH; Song TJ; Hwang JH; Yoo KS; Lee WJ; Lee KH; Dong SH; Park CH; Park ET; Moon JH; Kim HG; Kim EY; Cho KB; Kim HJ; Lee SO; Cheon YK; Lee JM; Oh DW; Kim MH
    Pancreatology; 2015; 15(4):405-10. PubMed ID: 25998516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Added value of diffusion-weighted imaging to MR cholangiopancreatography with unenhanced mr imaging for predicting malignancy or invasiveness of intraductal papillary mucinous neoplasm of the pancreas.
    Kang KM; Lee JM; Shin CI; Baek JH; Kim SH; Yoon JH; Han JK; Choi BI
    J Magn Reson Imaging; 2013 Sep; 38(3):555-63. PubMed ID: 23390008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The association between serum ferritin levels and malignant intraductal papillary mucinous neoplasms.
    Zhuge X; Zhou H; Chen L; Chen H; Chen X; Guo C
    BMC Cancer; 2021 Nov; 21(1):1253. PubMed ID: 34800987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MUC2 expression and prevalence of high-grade dysplasia and invasive carcinoma in mixed-type intraductal papillary mucinous neoplasm of the pancreas.
    Masuda A; Arisaka Y; Hara S; Matsumoto I; Takenaka M; Sakai A; Shiomi H; Matsuki N; Sugimoto M; Fujita T; Hayakumo T; Ku Y; Ogino S; Azuma T; Kutsumi H
    Pancreatology; 2013; 13(6):583-8. PubMed ID: 24280573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The natural history of main duct-involved, mixed-type intraductal papillary mucinous neoplasm: parameters predictive of progression.
    Roch AM; Ceppa EP; Al-Haddad MA; DeWitt JM; House MG; Zyromski NJ; Nakeeb A; Schmidt CM
    Ann Surg; 2014 Oct; 260(4):680-8; discussion 688-90. PubMed ID: 25203885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression profiling identifies genes associated with invasive intraductal papillary mucinous neoplasms of the pancreas.
    Sato N; Fukushima N; Maitra A; Iacobuzio-Donahue CA; van Heek NT; Cameron JL; Yeo CJ; Hruban RH; Goggins M
    Am J Pathol; 2004 Mar; 164(3):903-14. PubMed ID: 14982844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyst size indicates malignant transformation in branch duct intraductal papillary mucinous neoplasm of the pancreas without mural nodules.
    Sadakari Y; Ienaga J; Kobayashi K; Miyasaka Y; Takahata S; Nakamura M; Mizumoto K; Tanaka M
    Pancreas; 2010 Mar; 39(2):232-6. PubMed ID: 19752768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surgical outcomes of noninvasive and minimally invasive intraductal papillary-mucinous neoplasms of the pancreas.
    Takahashi H; Nakamori S; Nakahira S; Tsujie M; Takahshi Y; Marubashi S; Miyamoto A; Takeda Y; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
    Ann Surg Oncol; 2006 Jul; 13(7):955-60. PubMed ID: 16788757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MUC1 and HER2 might be associated with invasive phenotype of intraductal papillary mucinous neoplasm.
    Ohira G; Kimura K; Yamada N; Amano R; Nakata B; Doi Y; Murata A; Yashiro M; Tanaka S; Ohsawa M; Wakasa K; Hirakawa K
    Hepatogastroenterology; 2013; 60(125):1067-72. PubMed ID: 23635475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "High-risk stigmata" of the 2012 international consensus guidelines correlate with the malignant grade of branch duct intraductal papillary mucinous neoplasms of the pancreas.
    Aso T; Ohtsuka T; Matsunaga T; Kimura H; Watanabe Y; Tamura K; Ideno N; Osoegawa T; Takahata S; Shindo K; Ushijima Y; Aishima S; Oda Y; Ito T; Mizumoto K; Tanaka M
    Pancreas; 2014 Nov; 43(8):1239-43. PubMed ID: 25036910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood fibrinogen levels discriminate low- and high-risk intraductal papillary mucinous neoplasms (IPMNs).
    Nentwich MF; Menzel K; Reeh M; Uzunoglu FG; Ghadban T; Bachmann K; Schrader J; Bockhorn M; Izbicki JR; Perez D
    Eur J Surg Oncol; 2017 Apr; 43(4):758-762. PubMed ID: 28131667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pancreatic main-duct involvement in branch-duct IPMNs: an underestimated risk.
    Fritz S; Klauss M; Bergmann F; Strobel O; Schneider L; Werner J; Hackert T; Büchler MW
    Ann Surg; 2014 Nov; 260(5):848-55; discussion 855-6. PubMed ID: 25379856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic accuracy of diffusion restriction in intraductal papillary mucinous neoplasm of the pancreas in comparison with "high-risk stigmata" of the 2012 international consensus guidelines for prediction of the malignancy and invasiveness.
    Kim M; Mi Jang K; Kim SH; Doo Song K; Jeong WK; Kang TW; Kim YK; Cha DI; Kim K; Yoo H
    Acta Radiol; 2017 Oct; 58(10):1157-1166. PubMed ID: 28084815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-glycosylation in non-invasive and invasive intraductal papillary mucinous neoplasm.
    Nieminen H; Nummela P; Satomaa T; Heiskanen A; Hiltunen JO; Kaprio T; Seppänen H; Hagström J; Mustonen H; Ristimäki A; Haglund C
    Sci Rep; 2023 Aug; 13(1):13191. PubMed ID: 37580349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonoperative management of main pancreatic duct-involved intraductal papillary mucinous neoplasm might be indicated in select patients.
    Roch AM; DeWitt JM; Al-Haddad MA; Schmidt CM; Ceppa EP; House MG; Zyromski NJ; Nakeeb A; Schmidt CM
    J Am Coll Surg; 2014 Jul; 219(1):122-9. PubMed ID: 24862887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma MicroRNAs as Novel Biomarkers for Patients with Intraductal Papillary Mucinous Neoplasms of the Pancreas.
    Permuth-Wey J; Chen DT; Fulp WJ; Yoder SJ; Zhang Y; Georgeades C; Husain K; Centeno BA; Magliocco AM; Coppola D; Malafa M
    Cancer Prev Res (Phila); 2015 Sep; 8(9):826-34. PubMed ID: 26314797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimally invasive intraductal papillary-mucinous carcinoma of the pancreas: clinicopathologic study of 104 intraductal papillary-mucinous neoplasms.
    Nara S; Shimada K; Kosuge T; Kanai Y; Hiraoka N
    Am J Surg Pathol; 2008 Feb; 32(2):243-55. PubMed ID: 18223327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of ductal carcinoma of the pancreas during follow-up of branch duct intraductal papillary mucinous neoplasm of the pancreas.
    Uehara H; Nakaizumi A; Ishikawa O; Iishi H; Tatsumi K; Takakura R; Ishida T; Takano Y; Tanaka S; Takenaka A
    Gut; 2008 Nov; 57(11):1561-5. PubMed ID: 18477671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.